Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Legal Officer | August 10, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date August 10, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,818 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 181,818 · Balance 181,818 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing August 10, 2027 and continuing through August 10, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing August 10, 2027 and continuing through August 10, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 477,738 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2020 Filed Jun 8, 2020 16:47 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 462 | $121.53 | $56,146.86 |
DisclosureSEC source: 0001567619-20-011850 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,040 F1 · balance_after: Includes 24,749 restricted stock units. F2 · balance_after: Includes 238 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 15, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:27 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005648 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,264 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 25,606 RSUs. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:24 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 932 | $118.01 | $109,985.32 |
DisclosureSEC source: 0001567619-20-000613 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,271 F1 · balance_after: Includes 20,613 restricted stock units. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 18:28 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,404 | $86.63 | $121,628.52 |
DisclosureSEC source: 0001567619-19-020474 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,203 F1 · balance_after: Includes 23,113 restricted stock units. Read SEC document |
| May 28, 2019 Filed May 30, 2019 17:40 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 3,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012440 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,607 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on June 4 of each year, beginning June 4, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 27,175 RSUs. F3 · balance_after: Includes 621 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 15, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 11:51 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,022 | $36.55 | $37,354.10 |
DisclosureSEC source: 0001567619-19-000437 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,561 F1 · balance_after: Includes 23,750 restricted stock units. F2 · balance_after: Includes 333 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 15, 2018. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 19:38 UTC | NEVRO CORP NVRO · Entity 12422 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001567619-18-007122 · doc1.xml · derivative · entry 2 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2028-11-26 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 27, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 19:38 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-007122 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on November 1 of each year, beginning November 1, 2019, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 26,250 RSUs. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:19 UTC | NEVRO CORP NVRO · Entity 12422 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001140361-17-046910 · doc1.xml · derivative · entry 2 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-12-17 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 18, 2017 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 17:19 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-046910 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on January 2 of each year, beginning January 2, 2019, subject to the Reporting Person's continued service to the issuer. F1 · balance_after: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on January 2 of each year, beginning January 2, 2019, subject to the Reporting Person's continued service to the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.